Free Trial
NASDAQ:AXGN

AxoGen Q3 2025 Earnings Report

AxoGen logo
$15.59 -0.40 (-2.50%)
Closing price 04:00 PM Eastern
Extended Trading
$15.81 +0.22 (+1.41%)
As of 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AxoGen EPS Results

Actual EPS
N/A
Consensus EPS
$0.09
Beat/Miss
N/A
One Year Ago EPS
N/A

AxoGen Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

AxoGen Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, November 6, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

AxoGen Earnings Headlines

Bitcoin grabs headlines, but smart money likes this token
Bitcoin grabs headlines, but smart money likes this token My research team has identified the token positioned at the absolute center of this incoming capital flood— a project so fundamentally essential to the crypto ecosystem that institutional investors simply cannot ignore it.tc pixel
Brokerages Set AxoGen, Inc. (NASDAQ:AXGN) Target Price at $25.75
Q3 Earnings Forecast for AxoGen Issued By HC Wainwright
See More AxoGen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AxoGen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AxoGen and other key companies, straight to your email.

About AxoGen

AxoGen (NASDAQ:AXGN) is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue. These proprietary platforms are supported by a direct sales force in the United States and strategic distributor partnerships in international markets.

AxoGen markets its technologies across North America, Europe, Australia and parts of Latin America, collaborating with surgeons in specialties such as hand, orthopedics, plastic and reconstructive surgery. The company leverages clinical training programs, peer-reviewed research and reimbursement support services to drive adoption of its nerve repair solutions. As it advances its product pipeline, AxoGen continues to seek regulatory clearances and expand its global footprint in the evolving field of peripheral nerve repair.

View AxoGen Profile

More Earnings Resources from MarketBeat